Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
US large, mid, and small-cap retirement index funds provide layered exposure to varying market segments. This intro covers allocation ideas and risk considerations.
26,127 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Benchmark analysts cheer Strategy’s pivot to STRC as the primary funding engine for bitcoin accumulation, signaling a...
A high-profile fund manager dumped a huge chunk of AMD stock in one day. The move sparked questions about portfolio s...
D-Wave Quantum stock is rallying on recent funding news and government support. This guide breaks down what that mean...
Two enormous EV players are positioned to leverage a multi-trillion AI opportunity. This article breaks down why thes...
This week brought a notable pullback in AI hardware names, including CoreWeave. Read a clear, practical look at what ...
When a CEO sells thousands of shares, investors want to know what it signals. This guide explains how to read insider...
SpaceX stock appears to be trading well below its IPO price, but price alone doesn’t determine value. Here’s a practi...
Two clean-energy names. One clear question: which has the better odds of delivering big returns for investors over th...
QuantumScape has fallen hard in early 2026. This guide walks you through what would move the stock higher, what could...
Rivian is expanding beyond its trucks and SUVs into self-driving tech and ridesharing partnerships. This guide breaks...
Rivian’s April milestone could reshape its growth path. This article breaks down why April could huge for Rivian, wha...